Ubs Group Ag Ascendis Pharma A/S Transaction History

Ubs Group Ag

$528 Billion
Q1 2025

A detailed history of Ubs Group Ag transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Ubs Group Ag holds 173,841 shares of ASND stock, worth $27.7 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

173,841

Previous 225,687 22.97%

Holding current value

$27.7 Million

Previous $31.1 Million 12.8%

% of portfolio

0.01%

Previous 0.01%

33 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	SELL	$119.49 - $168.84 $6.2 Million - $8.75 Million	-51,846 Reduced 22.97%	173,841 $27.1 Million
Q4 2024 Feb 14, 2025	BUY	$122.0 - $146.6 $26 Million - $31.3 Million	213,262 Added 1716.39%	225,687 $31.1 Million
Q3 2024 Nov 14, 2024	SELL	$113.0 - $153.43 $395,048 - $536,391	-3,496 Reduced 21.96%	12,425 $1.86 Million
Q2 2024 Aug 13, 2024	SELL	$121.07 - $153.67 $1.43 Million - $1.82 Million	-11,834 Reduced 42.64%	15,921 $2.17 Million
Q1 2024 May 13, 2024	SELL	$123.45 - $159.4 $21,233 - $27,416	-172 Reduced 0.62%	27,755 $4.2 Million
Q4 2023 Feb 09, 2024	SELL	$86.1 - $127.36 $1.32 Million - $1.95 Million	-15,304 Reduced 35.4%	27,927 $3.52 Million
Q3 2023 Nov 09, 2023	SELL	$86.5 - $103.97 $48,094 - $57,807	-556 Reduced 1.27%	43,231 $4.05 Million
Q2 2023 Aug 11, 2023	BUY	$69.96 - $97.84 $2.83 Million - $3.95 Million	40,416 Added 1198.93%	43,787 $3.91 Million
Q1 2023 May 12, 2023	BUY	$104.9 - $126.78 $78,779 - $95,211	751 Added 28.66%	3,371 $361,000
Q4 2022 Feb 08, 2023	SELL	$99.42 - $131.97 $623,661 - $827,847	-6,273 Reduced 70.54%	2,620 $319,000
Q3 2022 Nov 10, 2022	BUY	$84.03 - $110.23 $619,805 - $813,056	7,376 Added 486.22%	8,893 $918,000
Q2 2022 Aug 10, 2022	SELL	$78.08 - $117.61 $301,701 - $454,445	-3,864 Reduced 71.81%	1,517 $141,000
Q1 2022 May 16, 2022	SELL	$102.18 - $135.75 $102,180 - $135,750	-1,000 Reduced 15.67%	5,381 $631,000
Q4 2021 Feb 14, 2022	SELL	$127.1 - $169.66 $443,706 - $592,283	-3,491 Reduced 35.36%	6,381 $859,000
Q3 2021 Nov 15, 2021	SELL	$112.67 - $176.92 $130,922 - $205,581	-1,162 Reduced 10.53%	9,872 $1.57 Million
Q2 2021 Aug 13, 2021	BUY	$121.62 - $145.29 $970,041 - $1.16 Million	7,976 Added 260.82%	11,034 $1.45 Million
Q1 2021 May 12, 2021	SELL	$124.92 - $173.33 $25,983 - $36,052	-208 Reduced 6.37%	3,058 $394,000
Q4 2020 Feb 11, 2021	SELL	$151.2 - $182.76 $624,002 - $754,250	-4,127 Reduced 55.82%	3,266 $545,000
Q3 2020 Nov 12, 2020	BUY	$134.29 - $154.32 $503,721 - $578,854	3,751 Added 102.99%	7,393 $1.14 Million
Q2 2020 Jul 31, 2020	SELL	$110.87 - $156.01 $780,635 - $1.1 Million	-7,041 Reduced 65.91%	3,642 $538,000
Q1 2020 May 01, 2020	SELL	$97.01 - $145.11 $312,372 - $467,254	-3,220 Reduced 23.16%	10,683 $1.2 Million
Q4 2019 Feb 14, 2020	BUY	$91.45 - $139.12 $637,315 - $969,527	6,969 Added 100.5%	13,903 $1.93 Million
Q3 2019 Nov 14, 2019	BUY	$95.8 - $118.9 $73,766 - $91,553	770 Added 12.49%	6,934 $668,000
Q2 2019 Aug 14, 2019	BUY	$107.11 - $132.09 $69,407 - $85,594	648 Added 11.75%	6,164 $710,000
Q1 2019 May 14, 2019	SELL	$62.15 - $129.99 $100,496 - $210,193	-1,617 Reduced 22.67%	5,516 $650,000
Q4 2018 Feb 14, 2019	SELL	$55.16 - $69.67 $395,607 - $499,673	-7,172 Reduced 50.14%	7,133 $447,000
Q3 2018 Nov 14, 2018	BUY	$63.77 - $76.28 $292,831 - $350,277	4,592 Added 47.28%	14,305 $1.01 Million
Q2 2018 Aug 14, 2018	BUY	$58.55 - $73.92 $174,420 - $220,207	2,979 Added 44.24%	9,713 $646,000
Q1 2018 May 15, 2018	BUY	$38.98 - $68.04 $104,076 - $181,666	2,670 Added 65.7%	6,734 $440,000
Q4 2017 Feb 14, 2018	BUY	$31.98 - $40.38 $113,497 - $143,308	3,549 Added 689.13%	4,064 $163,000
Q3 2017 Nov 14, 2017	BUY	$26.89 - $37.1 $13,848 - $19,106	515 New	515 $19,000
Q2 2017 Aug 14, 2017	SELL	N/A	-959 Closed	0 $0
Q1 2017 Nov 14, 2017	BUY	N/A	959	959 $27,000

Others Institutions Holding ASND

# of Institutions

270

Shares Held

61.9M

Call Options Held

151K

Put Options Held

226K

View Full List

About Ascendis Pharma A/S

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $8.89B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

More about ASND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account